ImmunityBio, Inc. IBRX Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s cumulative cost basis?
- ImmunityBio, Inc. (IBRX) reported cumulative cost basis of $228.53M in Q1 2026.
- How has ImmunityBio, Inc.'s cumulative cost basis changed year-over-year?
- ImmunityBio, Inc.'s cumulative cost basis decreased by 4.1% year-over-year, from $238.21M to $228.53M.
- What is the long-term trend for ImmunityBio, Inc.'s cumulative cost basis?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s cumulative cost basis has grown at a 32.4% compound annual growth rate (CAGR), from $55.69M to $226.75M.